Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
Should orlistat be avoided in patients with a history of kidney stones?
Related Questions
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
What work up do you recommend in post bariatric surgery patients who are slowly gaining back the weight despite no changes in diet?
In patients with severe obesity, do you recommend a trial of GLP 1 R agonist therapy prior to bariatric surgery?
Would you consider changing a non-diabetic patient with obesity and a history of CAD who is on semaglutide to tirzepatide if they have not achieved their weight loss goals?
What do you recommend to your patients to prevent muscle loss when prescribing a GLP-1 agonist for weight loss?
How do you decide between bariatric surgery and a GLP-1 receptor agonist for patients with metabolic dysfunction-associated steatotic liver disease who have not met weight loss goals after six months of lifestyle interventions?
Should GLP-1 agonists be held during chemotherapy?